ASLAN Pharmaceuticals

CEO: Mr. Carl Firth
Founded In: 2010/04
Tel: 886-2-2758-3333
Fax: 886-2-2758-3321
Address: Room 3202, 32F, No. 333, Keelung Road, Xinyi Dist., Taipei, Taiwan


About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and breast cancer. ASLAN has several compounds in late stage development: varlitinib (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancers, and is entering pivotal studies for biliary tract cancer; and ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer.

Development Pipeline:

ASLAN 17 04 12 en